Our clinical program
VT1021 is Vigeo’s lead program, a small peptide agent derived from PSAP. VT1021 induces Tsp-1 production, which works through CD36 and CD47 to reprogram the tumor microenvironment and makes it inhospitable for tumor growth.
We have completed the dose escalation portion of first in human trial with VT1021 in early 2020. The expansion phase was initiated in March 2020, and enrolled subjects in pancreatic cancer, glioblastomas as well as a basket cohort including tumors expressing high levels of CD36 and CD47. Single agent activities have been observed in various solid tumor indications including glioblastoma.
Meanwhile, pipeline programs are in preclinical stages, and on track to generate novel therapies that will further validate Vigeo’s TIME-targeting approach.